Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI outshines doctors in predicting cataract surgery success?

NCT ID NCT07713069

Knowledge-focused Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial tests whether an artificial intelligence model called OCT-PRO can predict how well a person will see after cataract surgery more accurately than standard doctor predictions. The AI analyzes eye scans and other clinical data to forecast visual recovery. About 534 adults scheduled for cataract surgery will be randomly assigned to receive either an AI-assisted prediction or routine counseling. The goal is to see if the AI reduces the gap between expected and actual vision outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OCT-PRO prediction model (a device that uses AI to analyze OCT images and clinical data)
What this could lead to
If successful, this AI tool could help doctors and patients set more realistic expectations for vision after cataract surgery, reducing disappointment.
What could go wrong
The AI may not outperform experienced clinicians in all cases, and its accuracy depends on high-quality eye scans. The trial is relatively small and early-stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 534 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years scheduled to undergo phacoemulsification with intraocular lens (Phaco+IOL) implantation. * Outpatient diagnosis of senile, complicated, or metabolic cataract. * For bilateral cataracts, the eye with more advanced disease will be included. Exclusion Criteria: * History of amblyopia or neuro-ophthalmic disease in the operative eye. * Poor-quality OCT images precluding clear visualization of fundus structures. * Previous intraocular surgery in the operative eye. * Hearing or intellectual impairment preventing adequate cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.